It is, therefore, possible that Erk1/2i + CDK4/6i treatment, in addition to inducing mitochondrial-dependent MM cell killing, may inhibit PI altered RNA splicing and overcome PI drug resistance in MM. The gene discussed is MAPK3; the disease is Miyoshi myopathy.